Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1524-1532

  Zobair, Alya A Al ^a,b,d   Obeidy, Barrak F Al ^b,d   Yang, Lei ^b   Yang, Chunxu ^b   Hui, Yang ^a,b   Yu, Haijun ^a,c   Zheng, Fang ^b   Yang, Guifang ^c   Xie, Conghua ^a,b   Zhou, Fuxiang ^a,b   Zhou, Yunfeng ^a,b  

^a WUHAN UNIVERSITY   (China)

^b Hubei Cancer Clinical Study Center   (China)

^c ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^d UNIVERSITY OF MOSUL   (Iraq)

Author keywords

CXCL12; CXCR4; EGFR; NSCLC; Transactivation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; AGE; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DISTANT METASTASIS; DOWN REGULATION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TISSUE SECTION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CXCR4; SURVIVAL RATE;

EID: 84874712239     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2254     Document Type: Article

References (41)

1. Chen G, Wang Z, Liu XY and Liu FY: High-level CXCR4 expression correlates with brain-specific metastasis of non-small cell lung cancer. World J Surg 35: 56-61, 2011.
2. Dong J, Dai J, Shu Y, et al: Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. Carcinogenesis 31: 1080-1086, 2010.
3. Yang L, Li L, Chen Y and Parkin DM: Mortality time trends and the incidence and mortality estimation and projection for lung cancer in China. Zhongguo Fei Ai Za Zhi 8: 274-278, 2005 (In Chinese).
4. Yang L, Parkin DM, Ferlay J, Li L and Chen Y: Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 14: 243-250, 2005.
5. Van Dyke AL, Cote ML, Prysak GM, et al: COX-2/EGFR expression and survival among women with adenocarcinoma of lung. Carcinogenesis 29: 1781-1787, 2008.
6. Sung B, Jhurani S, Ahn KS, et al: Zerumbone down-regulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells. Cancer Res 68: 8938-8944, 2008.
7. Rahimi M, George J and Tang C: EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms. Int J Cancer 126: 1850-1860, 2010.
8. Tang CH, Tan TW, Fu WM and Yang RS: Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis 29: 35-43, 2008.
9. Kryczek I, Wei S, Keller E, Liu R and Zou W: Stromal-derived factor (SDF-1/CXCL2) and human tumor pathogenesis. Am J Physiol Cell Physiol 292: C987-C995, 2007.
10. Imai H, Sunaga N, Shimizu Y, et al: Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer. Int J Immunopathol Pharmacol 23: 153-164, 2010.
11. Andre F, Xia W, Conforti R, et al: CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist 14: 1182 1188, 2009.
12. Chinni RS, Yamamoto H, Dong Z, et al: CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposit in bone. Mol Cancer Res 6: 446-457, 2008.
13. Wong D and Korz W: Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res 14: 7975-7980, 2008.
14. Oonakahara K, Matsuyama W, Higashimoto I, et al: Stromal-derived factor-1alpha/CXCL12-CXCR 4 axis is involved in the dissemination of NSCLC cells into pleural space. Am J Respir Cell Mol Biol 30: 671-677, 2004.
15. Kijima T, Maulik G, Ma PC, et al: Regulation of cellular prolif¬eration, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 62: 6304-6311, 2002.
16. Phillips RJ, Burdick MD, Lutz M, et al: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167: 1676-1686, 2003.
17. Martínez-García E, Irigoyen M, González-Moreno O, et al: Repetitive nicotine exposure leads to a more malignant and metastasis-prone phenotype of SCLC: a molecular insight into the importance of quitting smoking during treatment. Toxicol Sci 116: 467-476, 2010.
18. Su L, Zhong J, Xu H, et al: Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res 11: 8273-8280, 2005.
19. Wagner PL, Hyjek E, Vazquez MF, et al: CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg 137: 615-621, 2009.
20. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643-655, 2005.
21. Morita S, Okamoto I, Kobayashi K, et al: Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutation. Clin Cancer Res 15: 4493 4498, 2009.
22. Liang Z, Zhang J, Zeng X, et al: Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer 10: 376, 2010.
23. Suzuki S, Dobashi Y, Yamane T, et al: Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer 103: 1265-1273, 2005.
24. Fischer OM, Hart S, Gschwind A and Ullrich A: EGFR signal transactivation in cancer cells. Biochem Soc Trans 31: 1203 1208, 2003.
25. Zaman SN, Resek ME and Robbins SM: Dual acylation and lipid raft association of Src-family protein tyrosine kinases are required for SDF-1/CXCL12-mediated chemotaxis in the Jurkat human T cell lymphoma cell line. J Leukoc Biol 84: 1082-1091, 2008.
26. Peipp M, Schneider-Merck T, Dechant M, et al: Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. J Immunol 180: 4338-4345, 2008.
27. Porcile C, Bajetto A, Barbieri F, et al: Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res 308: 241-253, 2005.
28. Guo Z, Cai S, Fang R, et al: The synergistic effects of CXCR4 and EGFR on promoting EGF-mediated metastasis in ovarian cancer cells. Colloids Surf B Biointerfaces 60: 1-6, 2007.
29. Cabioglu N, Summy J, Miller C, et al: CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 65: 6493-6497, 2005.
30. Cabioglu N, Gong Y, Islam R, et al: Expression of growth factor and chemokine receptors: new insight in the biology of inflam¬matory breast cancer. Ann Oncol 18: 1021-1029, 2007.
31. Wu Y G, Jin M, Xu H, et al: Clinicopathologic significance of HIF-1a, CXCR4, and VEGF expression in colon cancer. Clin Dev Immunol 7: 537531, 2010.
32. Spano JP, Andre F, Morat L, et al: Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 15: 613-617, 2004.
33. Ludovini V, Bellezza G, Pistola L, et al: High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20: 842-849, 2009.
34. Niemiec J, Kolodziejski L and Dyczek S: EGFR LI and Ki-67 LI are independent prognostic parameters influencing survivals of surgically treated squamous cell lung cancer patients. Neoplasma 52: 231-237, 2005.
35. Brabender J, Danenberg KD, Metzger R, et al: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7: 1850-1855, 2001.
36. Kanematsu T, Yano S, Uehara H, et al: Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 13: 289-298, 2003.
37. Meert AP, Martin B, Delmotte P, et al: The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 20: 975-981, 2002.
38. Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer 37 (Suppl 4): S9-S15, 2001.
39. Grisanti S, Rossi L, Ardighieri C, et al: CXCR4, EGFR and HER2 expression in patients with high-risk synovial sarcoma (SS): a clinicopathologic study. J Clin Oncol 24: 9580, 2006.
40. Phillips RJ, Mestas J, Gharaee-Kermani M, et al: Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/ mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280: 22473-22481, 2005.
41. Li YM, Pan Y, Wei Y, et al: Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6: 459-469, 2004.